348 related articles for article (PubMed ID: 24333142)
1. Mammalian target of rapamycin inhibitors permit regulatory T cell reconstitution and inhibit experimental chronic graft-versus-host disease.
Sugiyama H; Maeda Y; Nishimori H; Yamasuji Y; Matsuoka K; Fujii N; Kondo E; Shinagawa K; Tanaka T; Takeuchi K; Teshima T; Tanimoto M
Biol Blood Marrow Transplant; 2014 Feb; 20(2):183-91. PubMed ID: 24333142
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of calcineurin abrogates while inhibition of mTOR promotes regulatory T cell expansion and graft-versus-host disease protection by IL-2 in allogeneic bone marrow transplantation.
Satake A; Schmidt AM; Nomura S; Kambayashi T
PLoS One; 2014; 9(3):e92888. PubMed ID: 24658577
[TBL] [Abstract][Full Text] [Related]
3. [Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice].
Cao J; Li L; Chen C; Zeng LY; Li ZY; Pan XY; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):83-8. PubMed ID: 21429372
[TBL] [Abstract][Full Text] [Related]
4. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
5. Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts.
Giorgini A; Noble A
J Leukoc Biol; 2007 Nov; 82(5):1053-61. PubMed ID: 17684039
[TBL] [Abstract][Full Text] [Related]
6. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
7. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease.
Sakoda Y; Hashimoto D; Asakura S; Takeuchi K; Harada M; Tanimoto M; Teshima T
Blood; 2007 Feb; 109(4):1756-64. PubMed ID: 17032915
[TBL] [Abstract][Full Text] [Related]
8. Host Foxp3+CD4+ Regulatory T Cells Act as a Negative Regulator of Dendritic Cells in the Peritransplantation Period.
Inoue T; Ikegame K; Kaida K; Okada M; Yoshihara S; Tamaki H; Fujimori Y; Soma T; Ogawa H
J Immunol; 2016 Jan; 196(1):469-83. PubMed ID: 26621858
[TBL] [Abstract][Full Text] [Related]
9. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
Johnson BD; Becker EE; LaBelle JL; Truitt RL
J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models.
Duramad O; Laysang A; Li J; Ishii Y; Namikawa R
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1154-68. PubMed ID: 21145405
[TBL] [Abstract][Full Text] [Related]
11. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation.
Blazar BR; Taylor PA; Fitzsimmons WE; Vallera DA
J Immunol; 1994 Aug; 153(4):1836-46. PubMed ID: 7519216
[TBL] [Abstract][Full Text] [Related]
12. Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice.
Chen C; Cao J; Zeng L; Li Y; Wang D; Xu K
Transplant Proc; 2011 Jun; 43(5):2041-8. PubMed ID: 21693322
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
14. Selective Treg reconstitution during lymphopenia normalizes DC costimulation and prevents graft-versus-host disease.
Bolton HA; Zhu E; Terry AM; Guy TV; Koh WP; Tan SY; Power CA; Bertolino P; Lahl K; Sparwasser T; Shklovskaya E; Fazekas de St Groth B
J Clin Invest; 2015 Sep; 125(9):3627-41. PubMed ID: 26301814
[TBL] [Abstract][Full Text] [Related]
15. Double negative Treg cells promote nonmyeloablative bone marrow chimerism by inducing T-cell clonal deletion and suppressing NK cell function.
Su Y; Huang X; Wang S; Min WP; Yin Z; Jevnikar AM; Zhang ZX
Eur J Immunol; 2012 May; 42(5):1216-25. PubMed ID: 22539294
[TBL] [Abstract][Full Text] [Related]
16. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
[TBL] [Abstract][Full Text] [Related]
17. [Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation].
Yang K; Fan ZP; Liu QF; Zhang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):537-41. PubMed ID: 18495584
[TBL] [Abstract][Full Text] [Related]
18. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
19. Recipient-Derived Allo-iTregs Induced by Donor DCs Effectively Inhibit the Proliferation of Donor T Cells and Reduce GVHD.
Yang ZG; Wen RT; Feng JS; Cao PJ; Zhou HT; Liu WX
Anat Rec (Hoboken); 2019 May; 302(5):825-836. PubMed ID: 30312018
[TBL] [Abstract][Full Text] [Related]
20. Combined OX40L and mTOR blockade controls effector T cell activation while preserving T
Tkachev V; Furlan SN; Watkins B; Hunt DJ; Zheng HB; Panoskaltsis-Mortari A; Betz K; Brown M; Schell JB; Zeleski K; Yu A; Kirby I; Cooley S; Miller JS; Blazar BR; Casson D; Bland-Ward P; Kean LS
Sci Transl Med; 2017 Sep; 9(408):. PubMed ID: 28931653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
